[ad_1]
The pause comes at a time when reports suggest that the Moderna jab may have rare side effects, including heart inflammation.
Sweden and Denmark stated that they will suspend the use of Moderna’s COVID-19 vaccine for young people after reports of rare side effects such as myocarditis.
The Swedish health agency said on Wednesday that it will suspend the use of the vaccine for people born in 1991 and after, because data shows that young people who have been vaccinated and young people have increased myocarditis and pericarditis. These conditions involve inflammation of the heart or its lining.
The health agency said in a statement: “When it comes to Moderna’s vaccine, Spikevax, this link is particularly evident, especially after the second dose.” It added that the risk of being affected is very small.
Sweden’s chief epidemiologist Anders Tegnell stated that health agencies will continue to “watch the situation closely and act quickly to ensure that vaccination against COVID-19 is always as safe as possible while providing effective Protection” to combat this disease.
Danish health authorities said on Wednesday that in Denmark, due to precautions, Moderna vaccine will not be provided to people under 18 years of age.
It said that data collected from four Nordic countries showed that some people suspected that vaccination of Moderna vaccine would increase the risk of heart inflammation, although the number of cases of heart inflammation is still very low.
The preliminary data from the Nordic study has been sent to the Adverse Reaction Committee of the European Medicines Agency (EMA) and will now be evaluated.
Sweden and Denmark stated that they now recommend the Comirnaty vaccine from Pfizer/BioNTech.
Norway has recommended the Cominarty vaccine to minors and said on Wednesday that it is reiterating this point, emphasizing that rare side effects may be more frequent in boys and young men, and mainly after the second dose.
“Men under 30 should also consider Cominarty when vaccinated,” Geir Bukholm, head of infection control at the Norwegian Institute of Public Health, said in a statement.
Finnish health officials said that Finland is expected to announce its decision on Thursday.
EMA approved the use of Comirnaty in May, and Spikevax received approval for children over 12 years of age in July.
[ad_2]
Source link